Opiate drugs such as morphine are well known for their ability to produce potent analgesia as well as such unwanted side effects as tolerance, physical dependence, respiratory suppression and constipation. Opiates act at opioid receptors, which belong to the family of G protein-coupled receptors. The mechanisms governing mu opioid receptor ( m OR) regulation are of particular interest since morphine and other clinically important analgesics produce their pharmacological effects through this receptor. Here we review recent advances in understanding how opioid receptor regulation can impart differential agonist effi cacy produced in vivo.
INTRODUCTION
Of the three major classes of opioid receptors, mu ( m ), delta ( d ), and kappa ( k ), the m OR has proven to be the major target of opiate analgesics (for reviews see [1] [2] [3] ). The opioid receptors belong to the family of G protein-coupled receptors (GPCRs), and like most GPCRs, they can be regulated by multiple mechanisms including receptor desensitization, in ternalization, resensitization and downregulation. G protein-coupled receptor regulatory elements such as GPCR kinases (GRKs) and b arrestins are important mediators of these processes. Agonist stimulation of GPCRs promotes receptor phosphorylation by GRKs and leads to recruitment of b arrestins which effectively uncouple the receptor and G proteins, thus preventing further signaling. [4] [5] [6] In addition to mediating receptor desensitization, b arrestins also facilitate the internalization of inactivated receptors which can promote receptor recycling to the plasma membrane or lead to downregulation by receptor degradation. 4-6 b arrestins were fi rst described for their ability to negatively regulate GPCR signaling (ie, desensitization). 7 , 8 However, b arrestins can also play a more complex role in mediating receptor signaling and increasing evidence suggests that the complement of certain scaffolding proteins within the cellular environment may play a major role in determining overall receptor responsiveness to different agonists in particular cell types. 5 , 6 The role of b arrestins in regulating the m OR has been studied at both the molecular level in vitro and at the pharmacological level in vivo (for reviews see [9] [10] [11] [12] ). Early in vitro studies in transfected HEK-293 cells revealed that the m OR, upon activation with morphine, does not robustly recruit b arrestins to the membrane while other opioid agonists, such as etorphine, do. 13 Since agonist activation of GPCRs typically induces b arrestin recruitment, morphine ' s actions at the m OR are unusual. These early observations suggested that the morphine-bound m OR may not be regulated by b arrestins. However, the physiological importance of m OR-b arrestin interactions was soon revealed when morphine-induced behaviors were evaluated in mice lacking b arrestin2.
Mice lacking b arrestin2 appear normal, although this molecule has been implicated in regulating numerous GPCRs that are expressed throughout the body. When morphine is administered to these animals, striking differences become immediately apparent when they are compared with normal, wild-type (WT) mice. b arrestin2-knockout ( b arr2-KO) mice display enhanced and prolonged morphine-induced analgesia in both hot-plate and tail-fl ick antinociceptive tests. 14 , 15 Moreover, morphine-induced striatal extracellular dopamine levels as well as drug reinforcement are enhanced in the b arr2-KO mice compared with their WT counterparts. 16 Further investigation into behaviors in the absence of drug, revealed that basal tail-fl ick nociceptive response latencies are prolonged and this effect can be blocked by the opiate antagonist, naltrexone. 15 This suggests that the m ORb arrestin2 interaction may not only be important for regulating the morphine-activated receptor, but may also help to establish the basal tone of receptor signaling. This fi nding also correlates with the observation that m OR agonist stimulated G protein-coupling is elevated in b arr2-KO mouse brain regions (periaqueductal gray, brainstem) as well as spinal cord. 14 , 15 , 17 In the absence of agonist stimulation, the basal degree of m OR-G protein-coupling is also signifi cantly higher in brain regions in b arr2-KO compared with WT mice (LM Bohn, D Wang, W Sadée, unpublished observations). Therefore, the role of b arrestin2 in regulating the m OR is important for setting the basal tone as well as determining the potential for agonist-activated receptor signaling.
In the presence of persistent agonist treatment, GPCRs are subject to desensitization. Chronic morphine treatment, in vivo, leads to the development of opiate antinociceptive tolerance and physical dependence. Antinociceptive tolerance has previously been correlated with m OR desensitization 18 , 19 yet this has been diffi cult to test experimentally since there are no pharmacological tools which directly block desensitization. The b arr2-KO mice, after several different regimens of chronic morphine treatment, do not develop morphine-induced tolerance in the hot plate test, and display greatly attenuated tolerance in the tail-fl ick test. 15 , 17 Moreover, G protein-coupling in periaqueductal gray and brainstem of mice chronically treated with morphine reveal that while the m OR is signifi cantly uncoupled from G proteins in WT mice, coupling is preserved in the b arr2-KO mice. 17 In another set of studies, Przewlocka et al. 20 showed that intrathecal administration of b arrestin2-specifi c antisense oligonucleotides could delay the onset of morphine antinociceptive tolerance in mice. Taken together, the biochemical and behavioral data suggest that b arrestin2 acts as a negative regulator, or desensitizing component, of m OR signaling in vivo.
While many of the morphine-induced responses in the b arr2-KO mice support the classically defi ned role of b arrestins as negative regulators of GPCR signaling, other physiological and behavioral responses to morphine do not. Morphine is known to activate locomotor activity in mice; however, the b arr2-KO mice display less activation of locomotion compared with their WT counterparts despite increased extracellular dopamine levels in striatum. 16 Moreover, while the b arr2-KO mice are resistant to morphineinduced antinociceptive tolerance, both genotypes develop a similar extent of physical dependence. 17 Current studies of respiratory suppression and gastrointestinal transit suggest that morphine-induced side effects are also not enhanced and may be less severe in mice lacking b arrestin2 21 The question arises as to whether b arrestin2 may also be playing a role as a positive mediator of m OR signaling in vivo. Although b arrestins are traditionally viewed as negative regulators of GPCR signaling, b arrestins also function as scaffolding molecules that mediate GPCR signaling by facilitating interactions between signaling proteins and the receptor. In this scenario, m OR signaling may differ in certain cell types wherein the receptor ' s fate may be determined by the cellular complement of proteins within the receptor ' s immediate environment. Several in vitro studies have demonstrated that b arrestins act as adaptors between GPCRs and intracellular signaling proteins including the non-receptor tyrosine kinase, c-Src, 22-28 extracellular signalregulated kinases (ERK) 22 , 25 , 29-32 and c-Jun N-terminal kinase (JNK). 33 The role of b arrestin2 in modulating receptor signaling in vivo has been demonstrated by a recent study by Wang et al. 34 
The unbiquitination of b arrestins is yet another mechanism that plays a role in regulating b arrestin-mediated internalization and/or signaling via GPCRs. Agonist-stimulated ubiquitination of b arrestin2 has been implicated in co-traffi cking and subsequent endocytosis of several GPCRs. [35] [36] [37] The ubiquitinated receptor-b arrestin complex may also be important for initiating b arrestin-mediated signal transduction wherein endosomes containing receptor-b arrestin complexes may act as ' signalsomes ' by promoting receptor endocytosis as well as G-protein independent signaling. 37 However, such a role for b arrestins has yet to be demonstrated in m OR signaling.
It is apparent that the current understanding of GPCR signaling is rapidly expanding past the classical models of G-protein coupling and b arrestin-mediated desensitization. The complexity of determining receptor conformation, signaling and regulation is compounded by the organization of GPCRs into dimers and multimers. Interactions between receptors, as homo-, hetero-or oligo-mers, could change receptor expression profi les, ligand binding, and receptor signaling as well as traffi cking and regulation. Cvejic and Devi 38 reported that d opioid receptors ( d ORs) can exist as dimers in vitro and that the dimer complex can be desensitized in an agonist-dependent manner. Heterodimerization between d -and k ORs confers different receptor properties with distinct binding and signal transduction profi les compared with either the k -or d OR alone. 39 The m -and d ORs can heterodimerize and, in the presence of d -antagonists, m OR agonist binding and signaling is enhanced. 40 This fi nding was extended to animals wherein d -antagonists significantly augmented morphine-induced analgesia in mice. 40 Recently, Wang et al. 41 demonstrated that all three opioid receptors ( m , d , k ) have an equal potential to form homo-or heterodimers with each other. Interactions between opioid receptors and other receptor types including the b 2 -adrenergic, 42 nociceptin/orphanin FQ, 43 somatostatin receptors 44 , 45 and substance P receptors 46 have been reported in vitro and may further increase the level of complexity in conferring opioid receptor responsiveness.
Signaling via the m OR, therefore, has the potential to be regulated by multiple means. Even if the m OR is regulated by the classical desensitization paradigm by b arrestin2 in some neurons this may not hold true for other cell types. For example, the m OR is widely distributed throughout the CNS and periphery and therefore, m ORs expressed in one particular cell type (i.e medium spiny neurons) may not be subject to the same regulatory mechanisms as m ORs expressed in other cell types (ie, enteric neurons). Studies have shown decreased m OR-G protein coupling following morphine treatment in several brainstem regions of rat including the dorsal raphe nucleus, locus coeruleus, parabrachial nuclei, and the commissural nucleus tractus solitatius while no changes in m OR-G protein-coupling were observed in other regions such as the nucleus accumbens, amygdala, thalamus, and substania nigra. 19 Decreases in m OR activated G protein-coupling in the same regions affected by morphine (periaqueductal gray, locus coeruleus, and lateral parabrachial nucleus) were also seen in rats self-administering heroin. 47 Further, chronic morphine has been shown to induce desensitization of the m OR as measured by adenylyl cyclase inhibition in thalamus and periaqueductal gray brain regions but not in caudate putamen or nucleus accumbens. 18 These observations suggest that while the m OR is expressed in these brain regions, it is not desensitized to the same extent following chronic morphine treatment and demonstrates that the m OR can be differentially regulated in different cellular environments.
The relative responsiveness of the m OR is not only dependent on agonist occupancy but can vary with distinct opiate agonists. Several groups have demonstrated in vitro that while agonists such as morphine, DAMGO, etorphine, methadone and fentanyl can activate m OR signaling with similar effi cacy they differ in their ability to promote receptor desensitization and internalization. [48] [49] [50] For example, morphine and heroin do not promote robust b arrestin2 translocation or receptor endocytosis in HEK-293 cells while other opiate agonists including DAMGO, etorphine, methadone and fentanyl do. 13 , 50-55 The inability of morphine and heroin to induce b arrestin2 translocation could however be overcome by the overexpression of GRK2. 13 , 54 Studies in mouse embryonic fi broblasts lacking endogenous b arrestin1 and b arrestin2 suggest that the morphine-bound m OR preferentially interacts with b arrestin2. 54 This concept is further strengthened by the fi nding that the enhanced morphine analgesia in b arr2-KO mice could not be recapitulated in mice lacking b arrestin1, indicating that b arrestin2, rather than b arrestin1, may preferentially regulate the m OR in vivo. 54 Cheng et al. 56 showed that b arrestin1 interferes with d -and k OR stimulated G protein-coupling but had no effect on m OR activation of G proteins further supporting a selective interaction between the m OR and b arrestin2 rather than b arrestin1.
Studies in cell culture reveal that the morphine-bound m OR is weakly phosphorylated, a poor substrate for b arrestins, and does not internalize. However, the overexpression of b arrestins or GRKs can overcome these apparent limitations. 13 , 53 , 54 Therefore, it is reasonable that if a certain neuron expresses higher levels of b arrestins or GRKs, the m OR may be able to internalize with morphine binding. While studies have nicely shown different levels of GRK and b arrestin mRNA expression in certain brain regions, 57 a lack of selective antibody tools have made it diffi cult to quantify protein expression patterns of each GRK and b arrestin type.
Furthermore, GRK and b arrestin levels are dynamic and opiate agonists have been shown to alter their expression patterns throughout the CNS. Terwilliger et al. 58 reported that b arrestin1 and b arrestin2 levels increase in locus coeruleus neurons in response to chronic morphine treatment. In addition, acute and chronic morphine treatment also differentially alters b arrestin1 and b arrestin2 mRNA expression patterns in hippocampal, cerebral cortex, periaqueductal gray and locus coeruleus. 59 Mice acutely or chronically treated with the opiate agonist sufentanil have upregulated GRK2, GRK6 and b arrestin2 levels in brain while GRK3 levels are only elevated after acute treatment. 60 Increased levels of GRK2, GRK3, GRK6 and b arrestin2 in the cortex and striatum have also been observed following chronic opioid antagonist treatment with naloxone and naltrexone. 61 Finally, decreases in m OR density as well as GRK2, GRK6 and b arrestin2 levels in the prefrontal cortex have been observed in post-mortem brains of opiate addicts. 62 Overall, there is a great deal of evidence supporting the dynamic expression of GRKs and b arrestins in the central nervous system. Therefore, m OR regulation profi les may also be dynamic, dependent not only on the site of expression but also upon drug exposure. Recently, HaberstockDebic et al. 63 reported that while morphine-bound m ORs do not internalize in the cell body of neurons, receptor internalization does occur in the dendrites of the same hippocampal neuron. This observation further emphasizes and points to the importance of the immediate cellular environment to the overall receptor regulation. Upon considering both the cell culture and animal studies in parallel, it is apparent that opioid receptor regulation can have profound impacts on overall agonist responsiveness. The complexity governing such diverse potential regulatory mechanisms emphasizes the need to study receptor signaling in the endogenous environment as this may ultimately determine the physiological response to the drug. As these complexities are revealed, novel therapeutic targets may become available to enhance and fi ne-tune opioid receptor pharmacology for the treatment of pain and addiction.
